CytoPathfinder was inaugurated in 2004 as a drug discovery co-venture with the STF technology of the National Institute of Advanced Industrial Science and Technology, Japan (AIST).
Since then, we have established solid-phase transfection (STF) technology through studies carried out together with pharmaceutical companies and universities.
The STF method was developed at the Scripps Institute in the USA, and improved by AIST.
Our technology has been developed to help researchers who conduct gene function analysis aimed to improve the predictability of clinical development.
We also provide technologies that are useful in all aspects of research and development in industries related to human health.
We will continue to strive to provide highly reliable technology and share the findings of our research carried out in Japan with the rest of the world.
